Citations

Showing 10 of 108152 citations.

POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management
Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | May 17, 2021 | Volume: 96 | Issue: 7 | Pages: 872-888

10.1002/ajh.26240 | PMID 34000085 Get It

AbstractDisease overviewPOEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis.DiagnosisThe diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria.Risk stratificationBecause the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR.Risk‐adapted therapyFor those patients with a dominant plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement and for those who have progression of their disease 3–6 months after completing radiation therapy should receive systemic therapy. Corticosteroids are temporizing, but alkylators are the mainstay of treatment, either in the form of low dose conventional therapy or high dose with stem cell transplantation. Lenalidomide shows promise with manageable toxicity. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.
Leadership in Orthopaedic Surgery
Jildeh, Toufic R. , Hasan, Laith K. , Okoroha, Kelechi R. , Parsons, Theodore W.

Mayo Clinic

JBJS Reviews | May 17, 2021 | Volume: 9 | Issue: 4 | Pages: No page available

10.2106/jbjs.rvw.20.00187 | PMID 33982982 Get It

» Orthopaedic surgeons are expected to exercise leadership within a variety of departmental and organizational roles, such as in the context of the clinic, the operating room, private or academic practices, and, more broadly, their respective professional organizations. » Effective leadership can improve patient outcomes and satisfaction, as well as increase team efficacy and gratification. » Exercising insight and understanding as to how and when to employ different leadership styles can help orthopaedic surgeons lead effectively. Additionally, open and effective communication and emotional intelligence play an integral role in effective leadership. » This article reviews some of the current understanding regarding effective leadership in orthopaedic surgery, with a focus on highlighting strategies that are aimed at being a more effective leader.
Thinking Outside the Field: Two Cases of RT+ICI Synergy in Melanoma
Davidson, Tara M. , Yan, Yiyi , Zhang, Henan , Dong, Haidong , Grams, Michael P. , Park, Sean S.

Mayo Clinic

No container title available | May 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-455431/v1 Get It

Abstract While combination radiotherapy (RT) and immunotherapy is not novel there is still much to learn about this approach. Some initial pre-clinical and clinical evidence suggests triple therapy with RT and dual immune checkpoint blockade (anti-CTLA-4 + anti-PD-1/PD-L1) is a complimentary technique. We present two cases using the same novel regime of combination RT plus nivolumab and ipilimumab to treat metastatic melanoma. In both cases the burden of disease was significant within a lower extremity. Additionally, in both cases using this treatment plan, we were able establish sustained local disease control with additional systemic benefit which allowed both patients to avoid significant debility from surgical amputation. Given the response and safety we observed, this technique could be used as a potentially safe approach for future patients who are not eligible for traditional RT palliation or clinical trials.
Rapid Rise of Pediatric Telehealth During COVID-19 in a Large Multispecialty Health System
Howie, Flora, Kreofsky, Beth L. , Ravi, Anupama, Lokken, Troy G., Hoff, Mekenzie D., Fang, Jennifer L. , Lokken, Troy

Mayo Clinic

Telemedicine and e-Health | May 17, 2021 | Volume: 28 | Issue: 1 | Pages: 3-10

10.1089/tmj.2020.0562 | PMID 33999718 Get It

Background: Before the COVID-19 pandemic, telemedicine use for outpatient pediatric specialty care was low. Stay-at-home orders (SHO) prompted rapid upscaling of telemedicine capabilities and upskilling of providers. This study compares telemedicine usage before and after the SHO and analyzes how a Children's Center addressed challenges associated with a rapid rise in telemedicine. Methods: Data on outpatient visits across 14 specialty divisions were abstracted from the institutional electronic medical record. The 12-week study period (March 9, 2020–May 29, 2020) spanned three epochs: pre-SHO; post-SHO; reopening to in-person visits. Changes in in-person visits, video visits, and completed, cancelled, and no-show appointments were compared between three epochs. Results: A total of 4,914 outpatient pediatric specialty visits were completed, including 67% (3,296/4,914) in-person and 33% (1,618/4,914) through video. During the first two epochs encompassing the SHO, video visits increased by 4,750%. During the third epoch when the SHO was lifted, video visits decreased by 66%, with 19.4% of visits conducted through video in week 12. Overall, for outpatient video appointments, 82.8% (1,618/1,954) were completed, 9.1% (178/1,954) were cancelled, and 8.1% (158/1,954) were no-shows. The percentage of completed and no-show appointments did not differ between epochs. However, the cancellation rate decreased significantly from Epochs 1 to 3 (p = 0.008). Conclusion: A SHO was associated with a large increase in pediatric specialty video visits. Post-SHO, the percentage of pediatric specialty visits conducted through video decreased but remained higher than before the SHO. Frequent, content-rich communications, self-directed tutorials, and individualized coaching may facilitate successful increases in telemedicine use.
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly, Roisín M. , Leal, Jeffrey P. , Sólnes, Lilja B. , Huang, Chiung‐Yu , Carpenter, Ashley , Gaffney, Katy, Abramson, Vandana G. , Carey, Lisa A. , Liu, Minetta C. , Rimawi, Mothaffar F. , Specht, Jennifer M. , Storniolo, Anna Maria , Valero, Vicente , Krop, Ian E. , Camp, Melissa , Miller, Robert S. , Cimino‐Mathews, Ashley , Stearns, Vered , Abramson, Vandana G , Rimawi, Mothaffar , Specht, Jennifer , Vaklavas, Christos , Krop, Ian E , Winer, Eric , Miller, Robert S , Wolff, Antonio C , Cimino-Mathews, Ashley , Park, Ben Ho , Wahl, Richard L , Stearns, Vered , Carey, Lisa A , Huang, Chiung-Yu , Gaffney, Katy, Winer, Eric P. , Wolff, Antonio C. , Wahl, Richard L.

Mayo Clinic

Journal of Clinical Oncology | May 17, 2021 | Volume: 39 | Issue: 20 | Pages: 2247-2256

10.1200/jco.21.00280 | PMID 33999652 Get It

PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake value corrected for lean body mass (SULmax) on 18 F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) would predict pathologic complete response (pCR) to pertuzumab and trastuzumab (PT). PATIENTS AND METHODS Patients with stage II or III, estrogen receptor–negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. 18 F-labeled fluorodeoxyglucose positron emission tomography-computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percent change in SULmax by C1D15 predicting pCR is ≤ 0.65, with a one-sided type I error rate of 10%. RESULTS Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 22%. Receiver operator characteristic analysis of percent change in SULmax by C1D15 yielded an area under the curve of 0.72 (80% CI, 0.64 to 0.80; one-sided P = .12), which did not reject the null hypothesis. However, between patients who obtained pCR and who did not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 41.8%; P = .004) and SULmax reduction ≥ 40% was more prevalent (83% v 52%; P = .03; positive predictive value, 31%). Participants not obtaining a 40% reduction in SULmax by C1D15 were unlikely to obtain pCR (negative predictive value, 91%). CONCLUSION Although the primary objective was not met, early changes in SULmax predict response to PT in estrogen receptor–negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate tailoring of therapy in this setting.
The utility of diffusion tractography for speech preservation in laser ablation of the dominant insula: illustrative case
Kerezoudis, Panagiotis , Miller, Kai J. , Kaufmann, Timothy J. , Lehman, Vance T. , Wong‐Kisiel, Lily C.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | May 17, 2021 | Volume: 1 | Issue: 19 | Pages: No page available

10.3171/case21113 | PMID 35854831 Get It

BACKGROUND Open surgical treatment of insular epilepsy holds particular risk of injury to middle cerebral artery branches, the operculum (through retraction), and adjacent language-related white matter tracts in the language-dominant hemisphere. Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a surgical alternative that allows precise lesioning with potentially less operative risk. The authors presented the case of a 13-year-old girl with intractable, MRI-negative, left (dominant hemisphere) insular epilepsy that was treated with LITT. Diffusion tensor imaging (DTI) tractography was used to aid full posterior insular lesioning in the region of stereo electroencephalography–determined seizure onset while avoiding thermal injury to the language-related superior longitudinal fasciculus (SLF)/arcuate fasciculus (AF) and inferior fronto-occipital fasciculus (IFOF). OBSERVATIONS DTI tractography was used successfully in planning insular LITT and facilitated a robust insular ablation with sharp margins at the interfaces with the SLF/AF and IFOF. These tracts were spared, and no neurological deficits were induced through LITT. LESSONS Although it is technically demanding and has important limitations that must be understood, clinically available DTI tractography adds precision and confidence to insular laser ablation when used to protect important language-related white matter tracts.
The Emerging Role of Nanotechnology in Pursuit of Successful Drug Delivery to H3K27M Diffuse Midline Gliomas
Power, Erica A. , Rechberger, Julian S. , Lu, Victor M. , A Power, Erica, Power, Erica A , Rechberger, Julian S , Daniels, David J.

Mayo Clinic

Nanomedicine | May 17, 2021 | Volume: 16 | Issue: 16 | Pages: 1343-1346

10.2217/nnm-2021-0067 | PMID 33998840 Get It

Disease Flares in the Postpartum Period: Vigilance Is Key
Tirath, Ankita, Kane, Sunanda V.

Mayo Clinic

Inflammatory Bowel Diseases | May 17, 2021 | Volume: 28 | Issue: 3 | Pages: 484-485

10.1093/ibd/izab108 | PMID 33999156 Get It

COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies
Squire, Jacqueline D. , Caldera, Freddy , Caldera, Freddy , Squire, Jacqueline , Gonzalez‐Estrada, Alexei , Farraye, Francis A.

Mayo Clinic

Inflammatory Bowel Diseases | May 17, 2021 | Volume: 27 | Issue: 8 | Pages: 1358-1360

10.1093/ibd/izab094 | PMID 33999204 Get It

Treatment and Prognosis of Hepatic Epithelioid Hemangioendothelioma: A SEER Database Analysis
Chahrour, Mohamad A. , Khachfe, Hussein H. , El‐Asmar, Rudy, Saifi, Omran , Jamali, Faek R. , Habib, Joseph R.

Mayo Clinic

World Journal of Surgery | May 17, 2021 | Volume: 45 | Issue: 9 | Pages: 2886-2894

10.1007/s00268-021-06165-6 | PMID 33999226 Get It

AbstractBackgroundHepatic epithelioid hemangioendothelioma (HEH) is a rare tumor that can affect multiple organs. Little is known about the pathophysiology, clinical course and management of this disease. The aim of this study is to determine survival rates and elucidate the role of various prognostic factors and therapeutic modalities as compared to surgery on patients with HEH.MethodsA retrospective analysis on patients diagnosed with HEH between 2004 and 2016 was performed utilizing the SEER database. Kaplan–Meier curves were constructed to determine overall and cancer‐specific survival, and the log‐rank test was used to compare between groups. To explore prognostic factors and treatment outcomes, univariable and multivariable Cox proportional hazard models were developed.ResultsA total of 353 patients with HEH (median age: 50.4 years) were identified. The most common surgery performed was liver resection (90.8%). One‐year OS in the surgical group and non‐surgical group was 86.6% and 61.0%, respectively, while 5‐year OS was 75.2% and 37.4%, respectively. On multivariable analysis, surgery emerged as a favorable prognostic factor [HR (95%CI): 0.404 (0.215–0.758) p value = 0.005]. Age > 65 years [HR (95%CI): 2.548 (1.442–4.506) p value = 0.001] and tumor size > 10 cm [HR (95%CI): 2.401 (1.319–4.37) p value = 0.004] were shown to be poor survival prognostic factors.ConclusionHEH is a rare disease that is poorly understood. Surgical intervention is associated with improved survival rates. Multicenter prospective collaborations are needed to improve our limited knowledge about this neoplasm and determine the optimal treatment strategy.